» Articles » PMID: 22927817

Quantifying the Diversification of Hepatitis C Virus (HCV) During Primary Infection: Estimates of the in Vivo Mutation Rate

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2012 Aug 29
PMID 22927817
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus (HCV) is present in the host with multiple variants generated by its error prone RNA-dependent RNA polymerase. Little is known about the initial viral diversification and the viral life cycle processes that influence diversity. We studied the diversification of HCV during acute infection in 17 plasma donors, with frequent sampling early in infection. To analyze these data, we developed a new stochastic model of the HCV life cycle. We found that the accumulation of mutations is surprisingly slow: at 30 days, the viral population on average is still 46% identical to its transmitted viral genome. Fitting the model to the sequence data, we estimate the median in vivo viral mutation rate is 2.5×10⁻⁵ mutations per nucleotide per genome replication (range 1.6-6.2×10⁻⁵), about 5-fold lower than previous estimates. To confirm these results we analyzed the frequency of stop codons (N = 10) among all possible non-sense mutation targets (M = 898,335), and found a mutation rate of 2.8-3.2×10⁻⁵, consistent with the estimate from the dynamical model. The slow accumulation of mutations is consistent with slow turnover of infected cells and replication complexes within infected cells. This slow turnover is also inferred from the viral load kinetics. Our estimated mutation rate, which is similar to that of other RNA viruses (e.g., HIV and influenza), is also compatible with the accumulation of substitutions seen in HCV at the population level. Our model identifies the relevant processes (long-lived cells and slow turnover of replication complexes) and parameters involved in determining the rate of HCV diversification.

Citing Articles

analysis of the effect of HCV genotype-specific polymorphisms in Core, NS3, NS5A, and NS5B proteins on T-cell epitope processing and presentation.

Baig S, Berikkara A, Khalid R, Subhan S, Abbas T, Abidi S Front Microbiol. 2025; 15:1498069.

PMID: 39881992 PMC: 11774985. DOI: 10.3389/fmicb.2024.1498069.


Two Years of SARS-CoV-2 Omicron Genomic Evolution in Brazil (2022-2024): Subvariant Tracking and Assessment of Regional Sequencing Efforts.

Souza U, Spilki F, Tanuri A, Roehe P, Campos F Viruses. 2025; 17(1).

PMID: 39861853 PMC: 11768930. DOI: 10.3390/v17010064.


Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.

Sallam M, Khalil R Microorganisms. 2024; 12(6).

PMID: 38930417 PMC: 11205832. DOI: 10.3390/microorganisms12061035.


How robust are estimates of key parameters in standard viral dynamic models?.

Zitzmann C, Ke R, Ribeiro R, Perelson A PLoS Comput Biol. 2024; 20(4):e1011437.

PMID: 38626190 PMC: 11051641. DOI: 10.1371/journal.pcbi.1011437.


The social role of defective viral genomes in chronic viral infections: a commentary on Leeks et al. 2023.

Zhao L, Lythgoe K J Evol Biol. 2023; 36(11):1577-1581.

PMID: 37975505 PMC: 10880559. DOI: 10.1111/jeb.14244.


References
1.
Shin E, Park S, Demino M, Nascimbeni M, Mihalik K, Major M . Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C. Gastroenterology. 2011; 141(2):686-95, 695.e1. PMC: 3359650. DOI: 10.1053/j.gastro.2011.05.006. View

2.
Quinkert D, Bartenschlager R, Lohmann V . Quantitative analysis of the hepatitis C virus replication complex. J Virol. 2005; 79(21):13594-605. PMC: 1262582. DOI: 10.1128/JVI.79.21.13594-13605.2005. View

3.
Hoofnagle J . Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S21-9. DOI: 10.1053/jhep.2002.36227. View

4.
Sardanyes J, Sole R, Elena S . Replication mode and landscape topology differentially affect RNA virus mutational load and robustness. J Virol. 2009; 83(23):12579-89. PMC: 2786710. DOI: 10.1128/JVI.00767-09. View

5.
Layden-Almer J, Ribeiro R, Wiley T, Perelson A, Layden T . Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003; 37(6):1343-50. DOI: 10.1053/jhep.2003.50217. View